Key result
Anticardiolipin antibodies exhibit heterogeneity in avidity, cross-reactivity, specificity, and functional activity, which may explain variations in clinical presentation.
This review highlights the heterogeneity of anticardiolipin antibodies, which may explain variations in clinical presentations among patients.
May inform nuanced aCL interpretation in APS; leaves open validation of avidity-specific assays in prospective studies.
Antibodies detected by solid phase anticardiolipin immunoassays are heterogeneous but understanding the nature of this heterogeneity has proven difficult. Differences in any of the following features may account for differences in anticardiolipin antibodies: avidity for cardiolipin, phospholipid cross-reactivity, specificity for beta 2 glycoprotein I (beta 2GPI)-cardiolipin complexes, functional activity (as defined by the ability to inhibit phospholipid dependent coagulation reactions) and specificities for different conformations of phospholipids. Understanding these differences may be important in explaining the variations in clinical presentation of patients with these antibodies. This review attempts to define and discuss anticardiolipin heterogeneity.
No takes yet. Share an insight, caveat, or question.
Harris et al. (1994) conducted a review in Anticardiolipin antibodies. Anticardiolipin antibodies was evaluated. Anticardiolipin antibodies exhibit heterogeneity in avidity, cross-reactivity, specificity, and functional activity, which may explain variations in clinical presentation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: